8-K: Corbus Pharmaceuticals Announces Promising Early Data for Next-Generation Cancer Drug CRB-701

Corbus Pharmaceuticals' development partner, CSPC Pharmaceutical Group, presented encouraging Phase 1 clinical trial data for CRB-701 (SYS6002), a next-generation antibody-drug conjugate targeting nectin-4 positive tumors, at the 2024 ASCO Genitourinary Cancers Symposium.

Summary

• Corbus Pharmaceuticals announced data from an ongoing Phase 1 clinical trial for their drug candidate CRB-701 (SYS6002), which is being developed in partnership with CSPC Pharmaceutical Group.
• The trial is a dose escalation study in China, enrolling patients with metastatic urothelial cancer and other solid tumors that are confirmed to be nectin-4 positive.
• The data presented covers the first 18 patients across six dose cohorts (0.2-3.6 mg/kg) through December 2023, with the study having commenced in January 2023.
• CRB-701 was well-tolerated, with most adverse events being grade one or two and reversible, and no adverse events above grade three were observed.
• No dose discontinuations or reductions occurred, although one participant had a temporary dose interruption.
• Pharmacokinetic data suggests that the drug's components increase proportionally with the dose, and no accumulation was observed.
• Compared to enfortumab vedotin (EV), CRB-701 showed lower free MMAE concentrations.
• At doses of 2.7 mg/kg and above, which are considered therapeutically relevant, the drug demonstrated an objective response rate (ORR) of 43% and a disease control rate (DCR) of 71% in a mixed tumor population of 7 patients.
• The longest observed response is 11 cycles, which is approximately 10 months, and is still ongoing.
• All nectin-4 positive mUC and cervical cancer patients at doses of 2.7 mg/kg or higher showed some level of disease control.

Sentiment

Score: 8

Explanation: The document presents very positive early clinical data for CRB-701, highlighting its potential advantages over existing treatments. The absence of severe side effects and the encouraging efficacy results contribute to a strong positive sentiment.

Positives

• CRB-701 shows a promising safety profile with no severe adverse events reported.
• The drug has demonstrated encouraging efficacy with a 43% ORR and 71% DCR at therapeutically relevant doses.
• CRB-701 appears to have a differentiated PK profile compared to enfortumab vedotin (EV), with lower free MMAE concentrations.
• The absence of peripheral neuropathy and skin rash is a significant advantage over existing treatments like Padcev.
• The study is progressing with dose escalation ongoing and expansion planned.
• The company is planning to commence a clinical study in the US in Q1 2024.

Negatives

• The data is from a small sample size of 18 patients, with efficacy data based on only 7 patients at the therapeutically relevant dose.
• Two of the three partial responses are unconfirmed.
• The study is still in Phase 1, and further trials are needed to confirm the efficacy and safety of CRB-701.
• The study is being conducted in China, and results may not be directly applicable to other populations.

Risks

• The clinical trial is still in its early stages, and the results may not be replicated in larger studies.
• The drug's efficacy and safety need to be confirmed in a larger and more diverse patient population.
• There is competition from other companies developing similar treatments.
• The company is dependent on its development partner, CSPC Pharmaceutical Group, for the ongoing trial in China.
• The company is subject to the risks associated with clinical development, regulatory approvals, and commercialization of new drugs.

Future Outlook

Corbus is planning to commence a clinical study in the US in Q1 2024 and additional data presentations are planned for later this year. The company is also focused on dose expansion and further investigation into the safety and efficacy of CRB-701.

Management Comments

• Dr. Yuval Cohen, CEO of Corbus, stated that CRB-701 appears to have a differentiated PK profile compared to EV, with a safety profile devoid of peripheral neuropathy and skin rash.
• Dr. Cohen believes this could translate into meaningful benefits for mUC patients and other nectin-4 positive solid tumors.
• Dr. Daniel P. Petrylak M.D., Professor of Medicine and Urology at Yale School of Medicine, shared that the clinical responses in nectin-4 positive mUC and cervical cancer patients are encouraging and the early clinical safety provides the first evidence that CRB-701 has clinical activity in multiple nectin-4 expressing tumors.

Industry Context

This announcement is significant as it presents a potential competitor to existing treatments like Padcev, which has limitations such as skin toxicities and peripheral neuropathy. CRB-701's differentiated safety profile and encouraging efficacy data could position it as a valuable option in the treatment of nectin-4 positive tumors.

Comparison to Industry Standards

• The document compares CRB-701 to enfortumab vedotin (Padcev), a currently approved Nectin-4 targeting ADC.
• Padcev has a 47% rate of serious adverse events, 61% dose interruptions, 34% dose reductions and 17% dose discontinuations, while CRB-701 has not reported any dose discontinuations or reductions.
• Padcev is associated with skin toxicities and peripheral neuropathy, while CRB-701 has not reported any cases of these side effects.
• Emerging clinical-stage competition such as BT8009 and 9MW-2821 also have high rates of adverse events, dose reductions and interruptions.
• CRB-701 is designed to address the unmet needs of Padcev by using a 3rd generation ADC with a stable linker to reduce free circulating MMAE, extend ADC half-life to reduce dosing frequency, and lower DAR to allow for higher dosing.

Stakeholder Impact

• Shareholders may react positively to the encouraging clinical data.
• Patients with nectin-4 positive tumors may benefit from a new treatment option with a potentially improved safety profile.
• Employees may be motivated by the progress of the company's drug development program.
• The company's development partner, CSPC Pharmaceutical Group, will continue to play a key role in the ongoing trial in China.

Next Steps

• The dose escalation study in China is ongoing.
• Corbus plans to commence a clinical study in the US in Q1 2024.
• Additional data presentations are planned for later this year.
• Dose expansion is underway in China.

Key Dates

Keywords

CRB-701, SYS6002, Nectin-4, Antibody-Drug Conjugate, ADC, Urothelial Cancer, Metastatic Cancer, Clinical Trial, Oncology, CSPC Pharmaceutical Group, ASCO GU, MMAE, Enfortumab Vedotin, Padcev